
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising company with a positive outlook due to the potential of its innovative ABC platform and its investigational medicines, tarcocimab tedromer, KSI-501, and KSI-101. The recent stellar data from the GLOW2 trial and the anticipated pivotal data in 3Q26, 4Q26, and 2Q27 make Kodiak a strong buy. However, there may be financing risks and competition from other big biopharma companies to keep an eye on.
Bears say
Kodiak Sciences is a pre-commercial biotechnology company with a focus on developing and commercializing transformative therapies for retinal diseases using its proprietary ABC platform. Despite the company's promising pipeline, there are potential risks surrounding future clinical data and regulatory approvals, as well as the need for additional financing. Furthermore, the company's stock price has been volatile, which is not uncommon for developmental companies in the biotechnology sector. The success of Kodiak's investigational medicines, tarcocimab tedromer (Zenkuda), KSI-501, and KSI-101, will be key factors in determining the company's future financial performance and overall success.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares